For over 20 years, Takara Bio has been contributing to improve the health of humankind through the development of revolutionary biotechnologies that have supported researchers in making breakthroughs in cell & gene immunotherapy.
We are thrilled to announce that our symposium on “Emerging strategies to improve cell & gene immunotherapies” will take place in London on October 12th as a pre-event to the Immuno UK conference.
This half-day symposium will gather international leaders in the field of cell & gene immunotherapy to present their ground-breaking work on key topics, including new modalities for increased efficacy of CART-T cell therapy and innovative cell-based therapy approaches.
We look forward to seeing you at the symposium!
*Below times are BST (UTC+1)
Welcome & Intro
MATTHIEU PESANT, Takara Bio Europe
Talk 1: Stem-Like T Cell Responses In Cancer
ENRICO LUGLI, Principle Investigator, Laboratory of Translational Immunology, Humanitos Flow Cytometry Core, Humanitas Clinical & Research Center, Rozzano, Italy
T cells with stem-like properties have an established role in mediating cancer regression upon adoptive transfer of genetically-modified cells. More recently, we have identified heterogeneity within the exhausted T cell compartment in solid tumors, where stem-like progenitors mediate superior response to immune checkpoint blockade. In this talk, I will illustrate the cellular and molecular basis of stem-like T cell responses in physiology and cancer, with a special focus on the interaction between these cells and the tumor microenvironment.
Talk 2: CAR T-Cell Immunotherapy Of Solid Tumours – Learning From The Clinic & Lab In Parallel
JOHN MAHER, Consultant & Senior Lecturer, Immunology, Kings College London
The first part of my presentation will provide an update on a phase 1 clinical trial of a panErbB targeted second generation CAR T cell approach for relapsed refractory head and neck cancer. CAR T cells are. Manufactured from a blood draw and delivered using intra-tumoural injection. This will be followed by a presentation of a more recently developed “parallel CAR” system that is designed to deliver an optimal blend of activating and co-stimulatory signals. Exemplification of the technology will be presented for a range of targets found in solid tumours and haematological malignancies.
Talk 3: Tumor-Targeted Gene-Based Delivery Of Interferon Reprograms The Immunosuppressive Glioblastoma Microenvironment Towards Protective Immunity & Synergizes With CAR-T Cell Therapy To Eradicate The Tumor In Mouse Models
LUIGI NALDINI, Director SR-Tiget, San Raffaele Telethon Institute for Gene Therapy, Milano Italy
Our study addresses a long-sought and until now unattained goal of cancer immunotherapy: targeted delivery of immune activating cytokines to a treatment-refractory tumor like glioblastoma, reversing its strongly immune suppressive microenvironment (TME) and unleashing the protective action of adaptive immunity, while at the same time avoiding the systemic and off-target toxicities that have constrained their safe and successful clinical application.
Talk 4: Developing The Next Generation Of TCR-T Therapies For Cancer
ANDREW SEWELL, Distinguished Research Professor and Wellcome Trust Senior Investigator, Division of Infection & Immunity, Cardiff University School of Medicine, UK
Rollout of chimeric antigen receptor (CAR)-T therapy has been hampered by a lack of suitable targets on most cancer types. Tumour-infiltrating lymphocyte (TIL) and T-cell checkpoint blockade therapies have generated complete remissions of some cancers in some patients and renewed interest in T-cell receptor (TCR)-T therapy. Conventional TCRs can scan the entire proteome to access a far greater range of cancer-specific targets than CARs. However, recognition is dependent on specific human leukocyte antigen (HLA) molecules and the wide variation in HLA across the population means that any conventional TCR-T therapy is only applicable for a minority of patients. We have screened donors that have cleared end stage solid tumours for dominant anti-tumour T-cell clonotypes during and after complete solid cancer remission. Several new antigen discovery pipelines have allowed us to show that these T-cells often see new epitopes from antigens that are shared by many cancer types. Rarely, these clonotypes do not recognise cancers via HLA molecules but instead use conserved molecular platforms to distinguish between cancer cells and healthy cells. The TCRs from these broadly tumoricidal, HLA-agnostic T-cells offer hope for future development of pan-cancer, pan-population therapies that bypass the limitation of HLA-restriction.
Expert Panel Discussion
Panel formed of all above speakers
Conclusions & Closing of Symposium
Submit your details to watch the workshop recording.